Dostarlimab is a humanized anti-PD-1 monoclonal antibody that binds to human PD-1 with high affinity and competitively inhibits its interaction with the ligands PD-L1 and PD-L2 (IC50s of 1.8 nM and 1.5 nM, respectively); it is used for research purposes in immuno-oncology to study PD-1/PD-L1 pathway blockade and its effects on immune activation and tumor suppression.